Lipid nanomedicines for anticancer drug therapy

Journal of Biomedical Nanotechnology

Volumn 5, Issue 4, 2009, Pages 323-343

  De Mendoza, Ander Estella Hermoso ^a   Campanero, Miguel A ^b   Mollinedo, Faustino ^c   Blanco Prieto, María J ^a  

^a UNIVERSITY OF NAVARRA   (Spain)

^b Clinica Universitaria   (Spain)

^c Centro de Investigacion del Cancer   (Spain)

Author keywords

Antineoplastic; Cancer; Nanomedicines; SLN; Solid lipid nanoparticles

Indexed keywords

ANTICANCER DRUG; BODY TEMPERATURE; CANCER CELLS; CHEMOTHERAPEUTIC AGENTS; DRUG DELIVERY SYSTEM; HYDROPHOBIC AND HYDROPHILIC; LARGE SCALE PRODUCTIONS; LIPID MATRIX; LOW COSTS; NANOMEDICINES; NANOPARTICULATE SYSTEM; OXIDATIVE DEGRADATION; POOR STABILITY; POTENTIAL DRUG; SCALING-UP; SOLID LIPID NANOPARTICLES; SUBMICRON SIZE; SUSTAINED RELEASE; TUMOR CELLS;

CHEMOTHERAPY; DRUG DELIVERY; MEDICAL NANOTECHNOLOGY; NANOPARTICLES; PHOSPHOLIPIDS;

BIODEGRADABLE POLYMERS;

7 ETHYL 10 HYDROXYCAMPTOTHECIN; ANTINEOPLASTIC AGENT; BETA ELEMENE; CAMPTOTHECIN; CHLORAMBUCIL; CHOLESTERYL BUTIRATE; CISPLATIN; DNA; DOCETAXEL; DOXORUBICIN; EDELFOSINE; ETOPOSIDE; FLOXURIDINE; FLUOROURACIL; IDARUBICIN; METHOTREXATE; MITOXANTRONE; NAVELBINE; PACLITAXEL; RETINOIC ACID; SOLID LIPID NANOPARTICLE; TAMOXIFEN; UNCLASSIFIED DRUG;

ANTINEOPLASTIC ACTIVITY; AREA UNDER THE CURVE; ATOMIC FORCE MICROSCOPY; BIOCOMPATIBILITY; BIODEGRADABILITY; BODY TEMPERATURE; BREAST CANCER; CANCER CHEMOTHERAPY; CHEMICAL COMPOSITION; CHEMICAL REACTION; CHEMICAL STRUCTURE; CRYSTALLIZATION; DIFFERENTIAL SCANNING CALORIMETRY; DIFFUSION; DRUG ACCUMULATION; DRUG CYTOTOXICITY; DRUG DEGRADATION; DRUG DELIVERY SYSTEM; DRUG DISTRIBUTION; DRUG HALF LIFE; DRUG STABILITY; DRUG SYNTHESIS; EHRLICH ASCITES TUMOR; EVAPORATION; FREEZE DRYING; HUMAN; LIVER CELL CARCINOMA; LUNG CARCINOMA; LYMPH NODE METASTASIS; LYMPHOMA; MICROEMULSION; NANOEMULSION; NANOENCAPSULATION; NONHUMAN; PARTICLE SIZE; REVIEW; ROOM TEMPERATURE; SCALE UP; SURFACE PROPERTY; SUSTAINED DRUG RELEASE; TISSUE DISTRIBUTION; TOXICITY TESTING; ULTRASOUND; X RAY DIFFRACTION; ZETA POTENTIAL;

ANTINEOPLASTIC AGENTS; DRUG CARRIERS; DRUG COMPOUNDING; HUMANS; LIPIDS; NANOMEDICINE; NANOPARTICLES; NEOPLASMS;

EID: 70450175091     PISSN: 15507033     EISSN: 15507041     Source Type: Journal    
DOI: 10.1166/jbn.2009.1042     Document Type: Review

References (120)

1. R. B. Ewesuedo and M. J. Ratain, Oncologic Therapeutics, edited by E. E. Vokes and H. M. Golomb, Springer, New York (2003), pp. 19-66.
2. C. H. Takimoto and E. Calvo, Cancer Management: A Multidisciplinary Approach, 10th edn., edited by R. Pazdur, L. R. Coia, W. J. Hoskins, and L. D. Wagman, CMPMedica, Norwalk, CT, USA (2007).
3. G. Fontana, L. Maniscalco, D. Schillaci, G. Cavallaro, and G. Giammona, Solid lipid nanoparticles containing tamoxifen characterization and in vitro antitumoral activity. Drug Deliv. 12, 6 (2005).
4. A. Fundaro, R. Cavalli, A. Bargoni, D. Vighetto, G. P. Zara, and M. R. Gasco, Non-stealth and stealth solid lipid nanoparticles (SLN) carrying doxorubicin: pharmacokinetics and tissue distribution after i.v. administration to rats. Pharmacol. Res. 42, 4 (2000).
5. B. Lu, S. B. Xiong, H. Yang, X. D. Yin, and R. B. Chao, Solid lipid nanoparticles of mitoxantrone for local injection against breast cancer and its lymph node metastases. Eur. J. Pharm. Sci. 28, 1 (2006).
6. L. Serpe, M. G. Catalano, R. Cavalli, E. Ugazio, O. Bosco, R. Canaparo, E. Muntoni, R. Frairia, M. R. Gasco, M. Eandi, and G. P. Zara, Cytotoxicity of anticancer drugs incorporated in solid lipid nanoparticles on HT-29 colorectal cancer cell line. Eur. J. Pharm. Biopharm. 58, 3 (2004).
7. H. L. Wong, R. Bendayan, A. M. Rauth, Y. Li, and X. Y. Wu, Chemotherapy with anticancer drugs encapsulated in solid lipid nanoparticles. Adv. Drug Deliv. Rev. 59, 491 (2007).
8. W. J. Houlihan, M. Lohmeyer, P. Workman, and S. H. Cheon, Phospholipid antitumor agents. Med. Res. Rev. 15, 3 (1995).
9. F. Mollinedo, J. L. Fernandez-Luna, C. Gajate, B. Martin-Martin, A. Benito, R. Martinez-Dalmau, and M. Modolell, Selective induction of apoptosis in cancer cells by the ether lipid ET-18-OCH3 (Edelfosine): Molecular structure requirements, cellular uptake, and protection by Bcl-2 and BcI-X(L). Cancer Res. 57, 7 (1997).
10. W. E. Berdel and S. Okamoto, Ether lipids in cancer chemotherapy. Keio J. Med. 39, 2 (1990).
11. A. Estella-Hermoso de Mendoza, M. A. Campanero, J. de la Iglesia-Vicente, C. Gajate, F. Mollinedo, and M. J. Blanco-Prieto, Anti-tumour alkyl ether lipid edelfosine: Tissue distribution and pharmacokinetic behaviour in healthy and tumour-bearing immune suppressed mice. Clin. Cancer Res. 15, 858 (2009).
12. F. Mollinedo, C. Gajate, S. Martin-Santamaria, and F. Gago, ET-18-OCH3 (edelfosine): A selective antitumour lipid targeting apoptosis through intracellular activation of Fas/CD95 death receptor. Curr. Med. Chem. 11, 24 (2004).
13. C. Gajate and F. Mollinedo, The antitumor ether lipid ET-18-OCH(3) induces apoptosis through translocation and capping of Fas/CD95 into membrane rafts in human leukemic cells. Blood. 98, 13 (2001).
14. J. Kotting, N. W. Marschner, W. Neumuller, C. Unger, and H. Eibl, Hexadecylphosphocholine and octadecyl-methyl-glycero-3-phosphocholine: A comparison of hemolytic activity, serum binding and tissue distribution. Prog. Exp. Tumor Res. 34, 131 (1992).
15. S. London, Intermittent oxaliplatin dosing prolongs time to treatment failure. Oncol. News Int. 17 (2008).
16. K. Ruckmani, M. Sivakumar, and P. A. Ganeshkumar, Methotrexate loaded solid lipid nanoparticles (SLN) for effective treatment of carcinoma. J. Nanosci. Nanotechnol. 6, 9 (2006).
17. P. Speiser, Lipidnanopellets als tragersystem fur arzneimittel zur peroralen anwendung. Eur. Patent Appl. EP 0,167,825 (1986).
18. M. R. Gasco, Method for producing solid lipid microspheres having a narrow distribution. US Patent No. 5,250,236 (1993).
19. R. H. Müller and J. S. Lucks, Medication vehicles made of solid lipid particles (solid lipid nanospheres - SLN). European Patent No.0605497 (1996).
20. J. Y. Fang, C. L. Fang, C. H. Liu, and Y. H. Su, Lipid nanoparticles as vehicles for topical psoralen delivery: Solid lipid nanoparticles (SLN) versus nanostructured lipid carriers (NLC). Eur. J. Pharm. Biopharm. 70, 2 (2008).
21. W. Mehnert and K. Mader, Solid lipid nanoparticles: production, characterization and applications. Adv. Drug Deliv. Rev. 47, 2 (2001).
22. R. H. Muller, K. Mader, and S. Gohla, Solid lipid nanoparticles (SLN) for controlled drug delivery - A review of the state of the art. Eur. J. Pharm. Biopharm. 50, 1 (2000).
23. S. S. Shidhaye, R. Vaidya, S. Sutar, A. Patwardhan, and V. J. Kadam, Solid lipid nanoparticles and nanostructured lipid carriers-innovative generations of solid lipid carriers. Curr. Drug Deliv. 5, 4 (2008).
24. C. Olbrich and R. H. Muller, Enzymatic degradation of SLN-effect of surfactant and surfactant mixtures. Int. J. Pharm. 180, 1 (1999).
25. Y. Chen, G. Dalwadi, and H. A. Benson, Drug delivery across the blood-brain barrier. Curr. Drug Deliv. 1, 4 (2004).
26. I. P. Kaur, R. Bhandari, S. Bhandari, and V. Kakkar, Potential of solid lipid nanoparticles in brain targeting. J. Control. Rel. 127, 97 (2008).
27. P. R. Lockman, J. M. Koziara, R. J. Mumper, and D. D. Allen, Nanoparticle surface charges alter blood-brain barrier integrity and permeability. J. Drug Target. 12, 9 (2004).
28. R. H. Muller and C. M. Keck, Drug delivery to the brain-realization by novel drug carriers. J. Nanosci. Nanotechnol. 4, 5 (2004).
29. H. Bunjes, F. Steiniger, and W. Richter, Visualizing the structure of triglyceride nanoparticles in different crystal modifications. Langmuir. 23, 7 (2007).
30. A. Estella-Hermoso de Mendoza, M. Rayo, F. Mollinedo, and M. J. Blanco-Prieto, Lipid nanoparticles for alkyl lysophospholipid edelfosine encapsulation: Development and in vitro characterization. Eur. J. Pharm. Biopharm. 68, 2 (2008).
31. E. B. Souto, W. Mehnert, and R. H. Muller, Polymorphic behaviour of Compritol888 ATO as bulk lipid and as SLN and NLC. J. Microencapsul. 23, 4 (2006).
32. K. Manjunath, J. S. Reddy, and V. Venkateswarlu, Solid lipid nanoparticles as drug delivery systems. Meth. Find. Exp. Clin. Pharmacol. 27, 2 (2005).
33. A. zur Mühlen, C. Schwarz, and W. Mehnert, Solid lipid nanoparticles (SLN) for controlled drug delivery-drug release and release mechanism. Eur. J. Pharm. Biopharm. 45, 2 (1998).
34. M. Muchow, P. Maincent, and R. H. Muller, Lipid nanoparticles with a solid matrix (SLN, NLC, LDC) for oral drug delivery. Drug Dev. Ind. Pharm. 34, 12 (2008).
35. Z. R. Huang, S. C. Hua, Y. L. Yang, and J. Y. Fang, Development and evaluation of lipid nanoparticles for camptothecin delivery: A comparison of solid lipid nanoparticles, nanostructured lipid carriers, and lipid emulsion. Acta Pharmacol. Sin. 29, 9 (2008).
36. V. Jenning, K. Mader, and S. H. Gohla, Solid lipid nanoparticles (SLN) based on binary mixtures of liquid and solid lipids: a (1)H-NMR study. Int. J. Pharm. 205, 1 (2000).
37. H. L. Wong, A. M. Rauth, R. Bendayan, J. L. Manias, M. Ramaswamy, Z. Liu, S. Z. Erhan, and X. Y. Wu, A new polymer-lipid hybrid nanoparticle system increases cytotoxicity of doxorubicin against multidrug-resistant human breast cancer cells. Pharm. Res. 23, 1574 (2006).
38. R. H. Muller and C. M. Keck, Challenges and solutions for the delivery of biotech drugs-a review of drug nanocrystal technology and lipid nanoparticles. J. Biotechnol. 113, 1 (2004).
39. S. K. Jain, A. Chaurasiya, Y. Gupta, A. Jain, P. Dagur, B. Joshi, and V. M. Katoch, Development and characterization of 5-FU bearing ferritin appended solid lipid nanoparticles for tumour targeting. J. Microencapsul. 25, 5 (2008).
40. S. Markert, S. Lassmann, B. Gabriel, M. Klar, M. Werner, G. Gitsch, F. Kratz, and A. Hasenburg, Alpha-folate receptor expression in epithelial ovarian carcinoma and non-neoplastic ovarian tissue. Anticancer Res. 28, 6A (2008).
41. C. O. Evans, C. Yao, D. Laborde, and N. M. Oyesiku, Folate receptor expression in pituitary adenomas cellular and molecular analysis. Vitam. Horm. 79, 235 (2008).
42. Y. Lu, E. Sega, and P. S. Low, Folate receptor-targeted immunotherapy: Induction of humoral and cellular immunity against hapten-decorated cancer cells. Int. J. Cancer. 116, 5 (2005).
43. C. L. Denholt, P. R. Hansen, N. Pedersen, H. S. Poulsen, N. Gillings, and A. Kjaer, Identification of novel peptide ligands for the cancer-specific receptor mutation EFGRvIII using a mixture-based synthetic combinatorial library. Biopolymers 91, 3 (2009).
44. D. B. Cornelio, L. Meurer, R. Roesler, and G. Schwartsmann, Gastrin-releasing peptide receptor expression in cervical cancer. Oncology 73, 5 (2007).
45. K. Zhang, M. R. Aruva, N. Shanthly, C. A. Cardi, C. A. Patel, S. Rattan, G. Cesarone, E. Wickstrom, and M. L. Thakur, Vasoactive intestinal peptide (VIP) and pituitary adenylate cyclase activating peptide (PACAP) receptor specific peptide analogues for PET imaging of breast cancer In vitro/in vivo evaluation. Regul. Pept. 144, 1 (2007).
46. M. G. Caruso, C. Messa, A. Orlando, B. D'Attoma, and M. Notarnicola, Early induction of LDL receptor gene expression by genistein in DLD-1 colon cancer cell line. Fitoterapia 79, 7 (2008).
47. C. Peterson, S. Vitols, M. Rudling, H. Blomgren, F. Edsmyr, and L. Skoog, Hypocholesterolemia in cancer patients may be caused by elevated LDL receptor activities in malignant cells. Med. Oncol. Tumor Pharmacother. 2, 3 (1985).
48. H. Yuan, J. Miao, Y. Z. Du, J. You, F. Q. Hu, and S. Zeng, Cellular uptake of solid lipid nanoparticles and cytotoxicity of encapsulated paclitaxel in A549 cancer cells. Int. J. Pharm. 348, 1 (2008).
49. X. G. Zhang, J. Miao, Y. Q. Dai, Y. Z. Du, H. Yuan, and F. Q. Hu, Reversal activity of nanostructured lipid carriers loading cytotoxic drug in multi-drug resistant cancer cells. Int. J. Pharm. 361, 1 (2008).
50. S. M. Stephenson, P. S. Low, and R. J. Lee, Folate receptor-mediated targeting of liposomal drugs to cancer cells. Methods Enzymol. 387, 33 (2004).
51. P. J. Stevens, M. Sekido, and R. J. Lee, A folate receptor-targeted lipid nanoparticle formulation for a lipophilic paclitaxel prodrug. Pharm. Res. 21, 12 (2004).
52. M. N. Khalid, P. Simard, D. Hoarau, A. Dragomir, and J. C. Leroux, Long circulating poly(ethylene glycol)-decorated lipid nanocapsules deliver docetaxel to solid tumors. Pharm. Res. 23, 4 (2006).
53. R. Abou-Jawde, T. Choueiri, C. Alemany, and T. Mekhail, An overview of targeted treatments in cancer. Clin. Ther. 25, 8 (2003).
54. B. Stella, S. Arpicco, M. T. Peracchia, D. Desmaele, J. Hoebeke, M. Renoir, J. D'Angelo, L. Cattel, and P. Couvreur, Design of folic acid-conjugated nanoparticles for drug targeting. J. Pharm. Sci. 89, 11 (2000).
55. A. Beduneau, P. Saulnier, F. Hindre, A. Clavreul, J. C. Leroux, and J. P. Benoit, Design of targeted lipid nanocapsules by conjugation of whole antibodies and antibody Fab' fragments. Biomaterials 28, 33 (2007).
56. Y. Gupta, A. Jain, and S. K. Jain, Transferrin-conjugated solid lipid nanoparticles for enhanced delivery of quinine dihydrochloride to the brain. J. Pharm. Pharmacol. 59, 7 (2007).
57. S. J. Lim and C. K. Kim, Formulation parameters determining the physicochemical characteristics of solid lipid nanoparticles loaded with all-trans retinoic acid. Int. J. Pharm. 243, 1 (2002).
58. S. C. Yang, L. F. Lu, Y. Cai, J. B. Zhu, B. W. Liang, and C. Z. Yang, Body distribution in mice of intravenously injected camptothecin solid lipid nanoparticles and targeting effect on brain. J. Control. Rel. 59, 3 (1999).
59. L. H. Reddy, J. S. Adhikari, B. S. Dwarakanath, R. K. Sharma, and R. R. Murthy, Tumoricidal effects of etoposide incorporated into solid lipid nanoparticles after intraperitoneal administration in Dalton's lymphoma bearing mice. AAPS J. 8, 2 (2006).
60. L. H. Reddy, R. K. Sharma, K. Chuttani, A. K. Mishra, and R. R. Murthy, Etoposide-incorporated tripalmitin nanoparticles with different surface charge: formulation, characterization, radiolabeling, and biodistribution studies. AAPS J. 6, 3 (2004).
61. M. K. Lee, S. J. Lim, and C. K. Kim, Preparation, characterization and in vitro cytotoxicity of paclitaxel-loaded sterically stabilized solid lipid nanoparticles. Biomaterials 28, 12 (2007).
62. J. You, F. Wan, F. de Cui, Y. Sun, Y. Z. Du, and F. Q. Hu, Preparation and characteristic of vinorelbine bitartrate-loaded solid lipid nanoparticles. Int. J. Pharm. 343, 1 (2007).
63. Y. Hattori and Y. Maitani, Folate-linked lipid-based nanoparticle for targeted gene delivery. Curr. Drug Deliv. 2, 3 (2005).
64. K. Tabatt, C. Kneuer, M. Sameti, C. Olbrich, R. H. Muller, C. M. Lehr, and U. Bakowsky, Transfection with different colloidal systems: Comparison of solid lipid nanoparticles and liposomes. J. Control. Rel. 97, 2 (2004).
65. K. Tabatt, M. Sameti, C. Olbrich, R. H. Muller, and C. M. Lehr, Effect of cationic lipid and matrix lipid composition on solid lipid nanoparticle- mediated gene transfer. Eur. J. Pharm. Biopharm. 57, 2 (2004).
66. J. Tian, X. Pang, K. Yu, L. Liu, and J. Zhou, Preparation, characterization and in vivo distribution of solid lipid nanoparticles loaded with cisplatin. Pharmazie 63, 8 (2008).
67. P. Sharma, S. Ganta, W. A. Denny, and S. Garg, Formulation and pharmacokinetics of lipid nanoparticles of a chemically sensitive nitrogen mustard derivative: Chlorambucil. Int. J. Pharm. 367, 187 (2008).
68. Z. Xu, L. Chen, W. Gu, Y. Gao, L. Lin, Z. Zhang, Y. Xi, and Y. Li, The performance of docetaxel-loaded solid lipid nanoparticles targeted to hepatocellular carcinoma. Biomaterials 30, 2 (2009).
69. A. Miglietta, R. Cavalli, C. Bocca, L. Gabriel, and M. R. Gasco, Cellular uptake and cytotoxicity of solid lipid nanospheres (SLN) incorporating doxorubicin or paclitaxel. Int. J. Pharm. 210, 1 (2000).
70. G. P. Zara, R. Cavalli, A. Bargoni, A. Fundaro, D. Vighetto, and M. R. Gasco, Intravenous administration to rabbits of non-stealth and stealth doxorubicin-loaded solid lipid nanoparticles at increasing concentrations of stealth agent: pharmacokinetics and distribution of doxorubicin in brain and other tissues. J. Drug Target. 10, 4 (2002).
71. G. P. Zara, A. Bargoni, R. Cavalli, A. Fundaro, D. Vighetto, and M. R. Gasco, Pharmacokinetics and tissue distribution of idarubicin-loaded solid lipid nanoparticles after duodenal administration to rats. J. Pharm. Sci. 91, 5 (2002).
72. L. Serpe, M. Guido, R. Canaparo, E. Muntoni, R. Cavalli, P. Panzanelli, C. Delia Pepal, A. Bargoni, A. Mauro, M. R. Gasco, M. Eandi, and G. P. Zara, Intracellular accumulation and cytotoxicity of doxorubicin with different pharmaceutical formulations in human cancer cell lines. J. Nanosci. Nanotechnol. 6, 9 (2006).
73. M. Trotta, F. Debernardi, and O. Caputo, Preparation of solid lipid nanoparticles by a solvent emulsification-diffusion technique. Int. J. Pharm. 257, 1 (2003).
74. A. Del Pozo-Rodriguez, M. A. Solinis, A. R. Gascon, and J. L. Pedraz, Short- and long-term stability study of lyophilized solid lipid nanoparticles for gene therapy. Eur. J. Pharm. Biopharm. 71, 181 (2008).
75. R. Paliwal, S. Rai, B. Vaidya, K. Khatri, A. K. Goyal, N. Mishra, A. Mehta, and S. P. Vyas, Effect of lipid core material on characteristics of solid lipid nanoparticles designed for oral lymphatic delivery. Nanomedicine: Nanotechnology, Biology and Medicine. Corrected Proof, 5, 184 (2008).
76. R. Cortesi, E. Esposito, G. Luca, and C. Nastruzzi, Production of lipospheres as carriers for bioactive compounds. Biomaterials 23, 11 (2002).
77. M. Uner, Preparation, characterization and physico-chemical properties of solid lipid nanoparticles (SLN) and nanostructured lipid carriers (NLC): their benefits as colloidal drug carrier systems. Pharmazie 61, 5 (2006).
78. Y. Wang, Y. Deng, S. Mao, S. Jin, J. Wang, and D. Bi, Characterization and body distribution of beta-elemene solid lipid nanoparticles (SLN). Drug Dev. Ind. Pharm. 31, 8 (2005).
79. E. Zimmermann, R. H. Muller, and K. Mader, Influence of different parameters on reconstitution of lyophilized SLN. Int. J. Pharm. 196, 2 (2000).
80. W. N. Charman and V. J. Stella, Lymphatic Transport of Drugs, CRC Press, Boca Raton, FL, USA (1992).
81. J. Kreuter, Physicochemical characterization of polyacrylic nanoparticles. Int. J. Pharm. 14, 1 (1983).
82. M. Nidhin, R. Indumathy, K. J. Sreeram, and B. U. Nair, Synthesis of iron oxide nanoparticles of narrow size distribution on polysaccharide templates. Bull. Mater. Sci. 31, 1 (2008).
83. P. Ahlin, J. Kristl, A. Kristl, and F. Vrecer, Investigation of polymeric nanoparticles as carriers of enalaprilat for oral administration. Int. J. Pharm. 239, 1 (2002).
84. J. Stecova, W. Mehnert, T. Blaschke, B. Kleuser, R. Sivaramakrishnan, C. C. Zouboulis, H. Seitmann, H. C. Korting, K. D. Kramer, and M. Schafer-Korting, Cyproterone acetate loading to lipid nanoparticles for topical acne treatment: particle characterisation and skin uptake. Pharm. Res. 24, 5 (2007).
85. J. Zhang, Y. Fan, and E. Smith, Experimental design for the optimization of lipid nanoparticles. J. Pharm. Sci. 98, 1813 (2008).
86. N. Anton, J. P. Benoit, and P. Saulnier, Design and production of nanoparticles formulated from nano-emulsion templates-a review. J. Control. Rel. 128, 3 (2008).
87. C. Freitas and R. H. Muller, Effect of light and temperature on zeta potential and physical stability in solid lipid nanoparticles (SLN) dispersion. Int. J. Pharm. 168, 221 (1998).
88. N. Gadegaard, Atomic force microscopy in biology: technology and techniques. Biotech. Histochem. 81, 2 (2006).
89. H. Zhang, W. Cui, J. Bei, and S. Wang, Preparation of poly(lactide-co-glycolide-co-caprolactone) nanoparticles and their degradation behaviour in aqueous solution. Polym. Degrad Stab. 91, 9 (2006).
90. A. Radomska-Soukharev, Stability of lipid excipients in solid lipid nanoparticles. Adv. Drug Deliv. Rev. 59, 6 (2007).
91. T. Kramer, D. M. Kremer, M. J. Pikal, W. J. Petre, E. Y. Shalaev, and L. A. Gatlin, A procedure to optimize scale-up for the primary drying phase of lyophilization. J. Pharm. Sci. 98, 1 (2009).
92. P. Yadava, M. Gibbs, C. Castro, and J. A. Hughes, Effect of lyophilization and freeze-thawing on the stability of siRNA-liposome complexes. AAPS Pharm. Sci. Tech. 9, 2 (2008).
93. Y. Bensouda and A. Laatiris, The lyophilization of dispersed systems: influence of freezing process, freezing time, freezing temperature and RBCs concentration on RBCs hemolysis. Drug Dev. Ind. Pharm. 32, 8 (2006).
94. R. Seetharam, Y. Wada, S. Ramachandran, H. Hess, and P. Salir, Long-term storage of bionanodevices by freezing and lyophilization. Lab. Chip. 6, 9 (2006).
95. R. Cavalli, O. Caputo, and M. R. Gasco, Preparation and characterization of solid lipid nanospheres containing paclitaxel. Eur. J. Pharm. Sci. 10, 4 (2000).
96. C. Schwarz and W. Mehnert, Freeze-drying of drug-free and drug-loaded solid lipid nanoparticles (SLN). Int. J. Pharm. 157, 2 (1997).
97. R. H. Müller, S. Maassen, C. Schwarz, and W. Mehnert, Solid lipid nanoparticles (SLN) as potential carrier for human use: interaction with human granulocytes. J. Control. Rel. 47, 3 (1997).
98. N. Scholer, H. Hahn, R. H. Muller, and O. Liesenfeld, Effect of lipid matrix and size of solid lipid nanoparticles (SLN) on the viability and cytokine production of macrophages. Int. J. Pharm. 231, 2 (2002).
99. H. Weyhers, S. Ehlers, H. Hahn, E. B. Souto, and R. H. Muller, Solid lipid nanoparticles (SLN)-effects of lipid composition on in vitro degradation and in vivo toxicity. Pharmazie 61, 6 (2006).
100. M. D. Joshi and R. H. Muller, Lipid nanoparticles for parenteral delivery of actives. Eur. J. Pharm. Biopharm. 71, 2 (2009).
101. P. K. Dudeja, K. M. Anderson, J. S. Harris, L. Buckingham, and J. S. Coon, Reversal of multidrug resistance phenotype by surfactants: relationship to membrane lipid fluidity. Arch. Biochem. Biophys. 319, 1 (1995).
102. D. M. Woodcock, M. E. Linsenmeyer, G. Chojnowski, A. B. Kriegler, V. Nink, L. K. Webster, and W. H. Sawyer, Reversal of multidrug resistance by surfactants. Br. J. Cancer. 66, 1 (1992).
103. E. Allard, C. Passirani, E. Garcion, P. Pigeon, A. Vessieres, G. Jaouen, and J. P. Benoit, Lipid nanocapsules loaded with an organometallic tamoxifen derivative as a novel drug-carrier system for experimental malignant gliomas. J. Control. Rel. 130, 2 (2008).
104. D. B. Chen, T. Z. Yang, W. L. Lu, and Q. Zhang, In vitro and in vivo study of two types of long-circulating solid lipid nanoparticles containing paclitaxel. Chem. Pharm. Bull. (Tokyo) 49, 11 (2001).
105. L. H. Reddy, R. K. Sharma, K. Chuttanib, A. K. Mishrab, and R. S. R. Murth, Influence of administration route on tumor uptake and biodistribution of etoposide loaded solid lipid nanoparticles in Dalton's lymphoma tumor bearing mice. J. Control. Rel. 105, 185 (2005).
106. N. Scholer, C. Olbrich, K. Tabatt, R. H. Muller, H. Hahn, and O. Liesenfeld, Surfactant, but not the size of solid lipid nanoparticles (SLN) influences viability and cytokine production of macrophages. Int. J. Pharm. 221, 1 (2001).
107. A. Bargoni, R. Cavalli, O. Caputo, A. Fundaro, M. R. Gasco, and G. P. Zara, Solid lipid nanoparticles in lymph and plasma after duodenal administration to rats. Pharm. Res. 15, 5 (1998).
108. N. L. Trevaskis, W. N. Charman, and C. J. Porter, Lipid-based delivery systems and intestinal lymphatic drug transport: a mechanistic update. Adv. Drug Deliv. Rev. 60, 6 (2008).
109. G. P. Zara, R. Cavalli, A. Fundaro, A. Bargoni, O. Caputo, and M. R. Gasco, Pharmacokinetics of doxorubicin incorporated in solid lipid nanospheres (SLN). Pharmacol. Res. 40, 3 (1999).
110. H. Yuan, J. Chen, Y. Z. Du, F. Q. Hu, S. Zeng, and H. L. Zhao, Studies on oral absorption of stearic acid SLN by a novel fluorometric method. Colloids Surf. B Biointerfaces 58, 2 (2007).
111. L. Hu, X. Tang, and F. Cui, Solid lipid nanoparticles (SLNs) to improve oral bioavailability of poorly soluble drugs. J. Pharm. Pharmacol. 56, 12 (2004).
112. S. Peltier, J. M. Oger, F. Lagarce, W. Couet, and J. P. Benoit, Enhanced oral paclitaxel bioavailability after administration of paclitaxel-loaded lipid nanocapsules. Pharm. Res. 23, 6 (2006).
113. H. Chen, X. Chang, D. Du, W. Liu, J. Liu, T. Weng, Y. Yang, H. Xu, and X. Yang, Podophyllotoxin-loaded solid lipid nanoparticles for epidermal targeting. J. Control. Rel. 110, 2 (2006).
114. S. Yang, J. Zhu, Y. Lu, B. Liang, and C. Yang, Body distribution of camptothecin solid lipid nanoparticles after oral administration. Pharm. Res. 16, 5 (1999).
115. D. E. Owens, 3rd and N. A. Peppas, Opsonization, biodistribution, and pharmacokinetics of polymeric nanoparticles. Int. J. Pharm. 307, 1 (2006).
116. C. E. Soma, C. Dubernet, G. Barratt, S. Benita, and P. Couvreur, Investigation of the role of macrophages on the cytotoxicity of doxorubicin and doxorubicin-loaded nanoparticles on M5076 cells in vitro. J. Control. Rel. 68, 2 (2000).
117. J. Gualbert, P. Shahgaldian, and A. W. Coleman, Interactions of amphophilic calix[4]arene-based Solid Lipid Nanoparticles with bovine serum albumin. Int. J. Pharm. 257, 1 (2003).
118. N. Iodoshima, C. Udagawa, T. Ando, H. Fukuyasu, T. Watanabe, and S. Nakabayashi, Lipid nanoparticles for delivering antitumor drugs. Int. J. Pharm. 146, 81 (1997).
119. J. X. Wang, X. Sun, and Z. R. Zhang, Enhanced brain targeting by synthesis of 3′,5′-dioctanoyl-5-fluoro-2′-deoxyuridine and incorporation into solid lipid nanoparticles. Eur. J. Pharm. Biopharm. 54, 3 (2002).
120. L. H. Reddy, K. Vivek, N. Bakshi, and R. S. Murthy, Tamoxifen citrate loaded solid lipid nanoparticles (SLN): preparation, characterization, in vitro drug release, and pharmacokinetic evaluation. Pharm. Dev. Technol. 11, 2 (2006).